Reduction of high dose aspirin toxicity by dietary vitamin A
US4491574A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 2, 1983 |
| Grant date | Jan 1, 1985 |
| Priority date | — |
| Expiry date | Mar 2, 2003 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/60
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a development for alleviating the adverse side-effects of taking non-steroid analgesics and anti-inflammatory agents such as aspirin, by also ingesting vitamin A (or B-carotene) formulations. It has been found that vitamin A ingestion has a salutary and therapeutic effect, in that the vitamin A decreases toxicity, including ulcerogenesis, due to ingestion of such agents, e.g. aspirin. Aspirin per se is a very effective medication with pronounced analgesic properties, including the temporary relief of minor aches and pains, and is widely used (in small amounts) with no ill effects. However, since aspirin is a mild anti-coagulant, it sometimes causes bleeding of stomach ulcers, or aggravates pre-existing conditions of that nature. Thus the concomitant administration of vitamin A per se to humans taking aspirin is very effective in decreasing toxicity and inhibiting ulcerogenesis and bleeding in the stomach. Also effective, but less so, is B-carotene, a vitamin A precursor, which when assimilated into the body yields vitamin A or a derivative thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.